The authors provide theoretical and empirical evidence that suggests milestones, annual payments, and consulting are common because moral hazard, risk sharing, and adverse selection all play a role when embryonic inventions are licensed.
Link
Available for purchase at: http://papers.nber.org/papers/W11128